RICHMOND, Va. / May 28, 2024 / Business Wire / Owens & Minor, Inc. (NYSE: OMI), a global healthcare solutions company that provides healthcare products for home-based care, self-manufactured products, proprietary product portfolio, distribution services and innovative technology, announced today that Ed Pesicka, the Company’s President and Chief Executive Officer and Alex Bruni, the Company’s Executive Vice President and Chief Financial Officer, will participate in a webcasted fireside chat at 11:00 a.m. Eastern Daylight Time on Wednesday, May 29, 2024 at Leerink Partners’ Healthcare Crossroads Conference in Austin, Texas. Owens & Minor is also hosting one-on-one meetings with investors at the conference.
Please visit the investor relations page of the Owens & Minor website available at investors.owens-minor.com/events-and-presentations at least 10 minutes in advance to register for the live webcast of the discussion.
About Owens & Minor
Owens & Minor, Inc. (NYSE: OMI) is a Fortune 500 global healthcare solutions company providing essential products and services that support care from the hospital to the home. For over 100 years, Owens & Minor and its affiliated brands, Apria®, Byram® and HALYARD*, have helped to make each day better for the patients, providers, and communities we serve. Powered by more than 20,000 teammates worldwide, Owens & Minor delivers comfort and confidence behind the scenes so healthcare stays at the forefront. Owens & Minor exists because every day, everywhere, Life Takes Care™. For more information about Owens & Minor and our affiliated brands, visit owens-minor.com or follow us on LinkedIn and Instagram.
Last Trade: | US$6.93 |
Daily Change: | 0.16 2.36 |
Daily Volume: | 1,153,432 |
Market Cap: | US$534.370M |
February 28, 2025 February 11, 2025 February 03, 2025 December 02, 2024 November 04, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load